Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

A longitudinal characterization of the Non-Cystic Fibrosis Bronchiectasis airway microbiome.

Woo TE, Lim R, Heirali AA, Acosta N, Rabin HR, Mody CH, Somayaji R, Surette MG, Sibley CD, Storey DG, Parkins MD.

Sci Rep. 2019 May 3;9(1):6871. doi: 10.1038/s41598-019-42862-y.

2.

The effects of cycled inhaled aztreonam on the cystic fibrosis (CF) lung microbiome.

Heirali AA, Acosta N, Storey DG, Workentine ML, Somayaji R, Laforest-Lapointe I, Leung W, Quon BS, Berthiaume Y, Rabin HR, Waddell BJ, Rossi L, Surette MG, Parkins MD.

J Cyst Fibros. 2019 Mar 8. pii: S1569-1993(19)30028-1. doi: 10.1016/j.jcf.2019.02.010. [Epub ahead of print]

PMID:
30857926
3.

Pattern-Based Interpretation Criteria for 18F-Fludeoxyglucose Positron Emission Tomography/Computed Tomography in the Assessment of Pyogenic Spine Infection.

Kloiber R, Koslowsky IL, Tchajkov I, Rabin HR.

Can Assoc Radiol J. 2018 Nov;69(4):397-408. doi: 10.1016/j.carj.2018.06.004. Review. No abstract available.

PMID:
30390960
4.

Sputum microbiota is predictive of long-term clinical outcomes in young adults with cystic fibrosis.

Acosta N, Heirali A, Somayaji R, Surette MG, Workentine ML, Sibley CD, Rabin HR, Parkins MD.

Thorax. 2018 Nov;73(11):1016-1025. doi: 10.1136/thoraxjnl-2018-211510. Epub 2018 Aug 22.

PMID:
30135091
5.

Epidemiology and natural history of Pseudomonas aeruginosa airway infections in non-cystic fibrosis bronchiectasis.

Woo TE, Lim R, Surette MG, Waddell B, Bowron JC, Somayaji R, Duong J, Mody CH, Rabin HR, Storey DG, Parkins MD.

ERJ Open Res. 2018 Jun 18;4(2). pii: 00162-2017. doi: 10.1183/23120541.00162-2017. eCollection 2018 Apr.

6.

Diagnostic challenges in pyogenic spinal infection: an expanded role for FDG-PET/CT.

Yu GJ, Koslowsky IL, Riccio SA, Chu AKM, Rabin HR, Kloiber R.

Eur J Clin Microbiol Infect Dis. 2018 Mar;37(3):501-509. doi: 10.1007/s10096-018-3197-7. Epub 2018 Feb 6.

PMID:
29411191
7.

Group B streptococcus (GBS) is an important pathogen in human disease- but what about in cystic fibrosis?

Skolnik K, Nguyen A, Thornton CS, Waddell B, Williamson T, Rabin HR, Parkins MD.

BMC Infect Dis. 2017 Oct 2;17(1):660. doi: 10.1186/s12879-017-2729-6.

8.

The Evolving Cystic Fibrosis Microbiome: A Comparative Cohort Study Spanning 16 Years.

Acosta N, Whelan FJ, Somayaji R, Poonja A, Surette MG, Rabin HR, Parkins MD.

Ann Am Thorac Soc. 2017 Aug;14(8):1288-1297. doi: 10.1513/AnnalsATS.201609-668OC.

PMID:
28541746
9.

The effects of inhaled aztreonam on the cystic fibrosis lung microbiome.

Heirali AA, Workentine ML, Acosta N, Poonja A, Storey DG, Somayaji R, Rabin HR, Whelan FJ, Surette MG, Parkins MD.

Microbiome. 2017 May 5;5(1):51. doi: 10.1186/s40168-017-0265-7.

10.

Prevalence and Outcomes of Achromobacter Species Infections in Adults with Cystic Fibrosis: a North American Cohort Study.

Edwards BD, Greysson-Wong J, Somayaji R, Waddell B, Whelan FJ, Storey DG, Rabin HR, Surette MG, Parkins MD.

J Clin Microbiol. 2017 Jul;55(7):2074-2085. doi: 10.1128/JCM.02556-16. Epub 2017 Apr 26.

11.

Longitudinal sampling of the lung microbiota in individuals with cystic fibrosis.

Whelan FJ, Heirali AA, Rossi L, Rabin HR, Parkins MD, Surette MG.

PLoS One. 2017 Mar 2;12(3):e0172811. doi: 10.1371/journal.pone.0172811. eCollection 2017.

12.

Effect of freezing sputum on Pseudomonas aeruginosa population heterogeneity.

Poonja A, Heirali A, Workentine M, Storey DG, Somayaji R, Rabin HR, Surette MG, Parkins MD.

J Cyst Fibros. 2017 May;16(3):353-357. doi: 10.1016/j.jcf.2017.01.004. Epub 2017 Jan 24.

13.

Reemergence of Lower-Airway Microbiota in Lung Transplant Patients with Cystic Fibrosis.

Syed SA, Whelan FJ, Waddell B, Rabin HR, Parkins MD, Surette MG.

Ann Am Thorac Soc. 2016 Dec;13(12):2132-2142.

PMID:
27925791
14.

Virulence adaptations of Pseudomonas aeruginosa isolated from patients with non-cystic fibrosis bronchiectasis.

Woo TE, Duong J, Jervis NM, Rabin HR, Parkins MD, Storey DG.

Microbiology. 2016 Dec;162(12):2126-2135. doi: 10.1099/mic.0.000393.

15.

Long-term clinical outcomes of 'Prairie Epidemic Strain' Pseudomonas aeruginosa infection in adults with cystic fibrosis.

Somayaji R, Lam JC, Surette MG, Waddell B, Rabin HR, Sibley CD, Purighalla S, Parkins MD.

Thorax. 2017 Apr;72(4):333-339. doi: 10.1136/thoraxjnl-2015-208083. Epub 2016 Sep 28.

PMID:
27682327
16.

Assessment of the Microbial Constituents of the Home Environment of Individuals with Cystic Fibrosis (CF) and Their Association with Lower Airways Infections.

Heirali A, McKeon S, Purighalla S, Storey DG, Rossi L, Costilhes G, Drews SJ, Rabin HR, Surette MG, Parkins MD.

PLoS One. 2016 Feb 9;11(2):e0148534. doi: 10.1371/journal.pone.0148534. eCollection 2016.

17.

Development and Validation of a PCR Assay To Detect the Prairie Epidemic Strain of Pseudomonas aeruginosa from Patients with Cystic Fibrosis.

Workentine M, Poonja A, Waddell B, Duong J, Storey DG, Gregson D, Somayaji R, Rabin HR, Surette MG, Parkins MD.

J Clin Microbiol. 2016 Feb;54(2):489-91. doi: 10.1128/JCM.02603-15. Epub 2015 Dec 9.

18.

Epidemic Pseudomonas aeruginosa infection in patients with cystic fibrosis is not a risk factor for poor clinical Outcomes following lung transplantation.

Pritchard J, Thakrar MV, Somayaji R, Surette MG, Rabin HR, Helmersen D, Lien D, Purighalla S, Waddell B, Parkins MD.

J Cyst Fibros. 2016 May;15(3):392-9. doi: 10.1016/j.jcf.2015.11.004. Epub 2015 Dec 3.

19.

Clinical implications and characterization of Group A Streptoccoccus infections in adults with cystic fibrosis.

Skolnik K, Nguyen A, Somayaji R, Thornton CS, Waddell B, Surette MG, Rabin HR, Parkins MD.

BMC Pulm Med. 2015 Dec 12;15:161. doi: 10.1186/s12890-015-0157-1.

20.

Phenotypic and Genotypic Comparison of Epidemic and Non-Epidemic Strains of Pseudomonas aeruginosa from Individuals with Cystic Fibrosis.

Duong J, Booth SC, McCartney NK, Rabin HR, Parkins MD, Storey DG.

PLoS One. 2015 Nov 23;10(11):e0143466. doi: 10.1371/journal.pone.0143466. eCollection 2015.

21.

Infection control knowledge, beliefs and behaviours amongst cystic fibrosis patients with epidemic Pseudomonas aeruginosa.

Somayaji R, Waddell B, Workentine ML, Surette MG, Brager NP, Rabin HR, Parkins MD.

BMC Pulm Med. 2015 Nov 5;15:138. doi: 10.1186/s12890-015-0116-x.

22.

Antibiotic susceptibility and molecular mechanisms of macrolide resistance in streptococci isolated from adult cystic fibrosis patients.

Thornton CS, Grinwis ME, Sibley CD, Parkins MD, Rabin HR, Surette MG.

J Med Microbiol. 2015 Nov;64(11):1375-86. doi: 10.1099/jmm.0.000172. Epub 2015 Sep 25.

PMID:
26408040
23.

Prevalence and impact of Streptococcus pneumoniae in adult cystic fibrosis patients: a retrospective chart review and capsular serotyping study.

Thornton CS, Brown EL, Alcantara J, Rabin HR, Parkins MD.

BMC Pulm Med. 2015 May 2;15:49. doi: 10.1186/s12890-015-0041-z.

24.

Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response.

Lam JC, Somayaji R, Surette MG, Rabin HR, Parkins MD.

BMC Infect Dis. 2015 Mar 22;15:145. doi: 10.1186/s12879-015-0856-5.

25.

Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis.

Sadler MD, Crotty P, Fatovich L, Wilson S, Rabin HR, Myers RP.

Can J Gastroenterol Hepatol. 2015 Apr;29(3):139-44.

26.

Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Interpretation Criteria for Assessment of Antibiotic Treatment Response in Pyogenic Spine Infection.

Riccio SA, Chu AK, Rabin HR, Kloiber R.

Can Assoc Radiol J. 2015 May;66(2):145-52. doi: 10.1016/j.carj.2014.08.004. Epub 2015 Jan 13.

27.

Twenty-five-year outbreak of Pseudomonas aeruginosa infecting individuals with cystic fibrosis: identification of the prairie epidemic strain.

Parkins MD, Glezerson BA, Sibley CD, Sibley KA, Duong J, Purighalla S, Mody CH, Workentine ML, Storey DG, Surette MG, Rabin HR.

J Clin Microbiol. 2014 Apr;52(4):1127-35. doi: 10.1128/JCM.03218-13. Epub 2014 Jan 22.

28.

Metastatic bladder cancer presenting with persistent hematuria in young man with cystic fibrosis.

Patel P, Rabin HR, Vickers MM, Parkins MD.

Case Rep Pulmonol. 2013;2013:831871. doi: 10.1155/2013/831871. Epub 2013 May 14.

29.

Phenotypic heterogeneity of Pseudomonas aeruginosa populations in a cystic fibrosis patient.

Workentine ML, Sibley CD, Glezerson B, Purighalla S, Norgaard-Gron JC, Parkins MD, Rabin HR, Surette MG.

PLoS One. 2013;8(4):e60225. doi: 10.1371/journal.pone.0060225. Epub 2013 Apr 3.

30.

The cystic fibrosis airway microbiome.

Rabin HR, Surette MG.

Curr Opin Pulm Med. 2012 Nov;18(6):622-7. doi: 10.1097/MCP.0b013e328358d49a. Review.

PMID:
22965275
31.

Culture enriched molecular profiling of the cystic fibrosis airway microbiome.

Sibley CD, Grinwis ME, Field TR, Eshaghurshan CS, Faria MM, Dowd SE, Parkins MD, Rabin HR, Surette MG.

PLoS One. 2011;6(7):e22702. doi: 10.1371/journal.pone.0022702. Epub 2011 Jul 28.

32.

Stenotrophomonas maltophilia in cystic fibrosis: guilty or innocent?

Colin AA, Rabin HR.

Am J Respir Crit Care Med. 2011 Mar 1;183(5):564-6. doi: 10.1164/rccm.201010-1668ED. No abstract available.

PMID:
21471053
33.

Azithromycin paradox in the treatment of cystic fibrosis airway disease.

Sibley CD, Grinwis ME, Rabin HR, Surette MG.

Future Microbiol. 2010 Sep;5(9):1315-9. doi: 10.2217/fmb.10.99. No abstract available.

PMID:
20860478
34.

The Streptococcus milleri population of a cystic fibrosis clinic reveals patient specificity and intraspecies diversity.

Sibley CD, Sibley KA, Leong TA, Grinwis ME, Parkins MD, Rabin HR, Surette MG.

J Clin Microbiol. 2010 Jul;48(7):2592-4. doi: 10.1128/JCM.00414-10. Epub 2010 May 12.

35.

The genus Prevotella in cystic fibrosis airways.

Field TR, Sibley CD, Parkins MD, Rabin HR, Surette MG.

Anaerobe. 2010 Aug;16(4):337-44. doi: 10.1016/j.anaerobe.2010.04.002. Epub 2010 Apr 20.

PMID:
20412865
36.

Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients.

Grinwis ME, Sibley CD, Parkins MD, Eshaghurshan CS, Rabin HR, Surette MG.

Antimicrob Agents Chemother. 2010 Jul;54(7):2823-9. doi: 10.1128/AAC.01845-09. Epub 2010 Apr 19.

37.

McKay agar enables routine quantification of the 'Streptococcus milleri' group in cystic fibrosis patients.

Sibley CD, Grinwis ME, Field TR, Parkins MD, Norgaard JC, Gregson DB, Rabin HR, Surette MG.

J Med Microbiol. 2010 May;59(Pt 5):534-40. doi: 10.1099/jmm.0.016592-0. Epub 2010 Jan 21.

PMID:
20093379
38.

Characterization of Streptococcus milleri group isolates from expectorated sputum of adult patients with cystic fibrosis.

Grinwis ME, Sibley CD, Parkins MD, Eshaghurshan CS, Rabin HR, Surette MG.

J Clin Microbiol. 2010 Feb;48(2):395-401. doi: 10.1128/JCM.01807-09. Epub 2009 Dec 9.

39.

The relevance of the polymicrobial nature of airway infection in the acute and chronic management of patients with cystic fibrosis.

Sibley CD, Parkins MD, Rabin HR, Surette MG.

Curr Opin Investig Drugs. 2009 Aug;10(8):787-94. Review.

PMID:
19649923
40.

Discerning the complexity of community interactions using a Drosophila model of polymicrobial infections.

Sibley CD, Duan K, Fischer C, Parkins MD, Storey DG, Rabin HR, Surette MG.

PLoS Pathog. 2008 Oct;4(10):e1000184. doi: 10.1371/journal.ppat.1000184. Epub 2008 Oct 24.

41.

A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients.

Sibley CD, Parkins MD, Rabin HR, Duan K, Norgaard JC, Surette MG.

Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15070-5. doi: 10.1073/pnas.0804326105. Epub 2008 Sep 23.

42.

Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial).

Papaioannou A, Kennedy CC, Freitag A, Ioannidis G, O'Neill J, Webber C, Pui M, Berthiaume Y, Rabin HR, Paterson N, Jeanneret A, Matouk E, Villeneuve J, Nixon M, Adachi JD.

Chest. 2008 Oct;134(4):794-800. doi: 10.1378/chest.08-0608. Epub 2008 Jul 18.

43.

The Streptococcus milleri group--an unrecognized cause of disease in cystic fibrosis: a case series and literature review.

Parkins MD, Sibley CD, Surette MG, Rabin HR.

Pediatr Pulmonol. 2008 May;43(5):490-7. doi: 10.1002/ppul.20809. Review.

PMID:
18383109
44.

Pseudomonas aeruginosa cystic fibrosis isolates from individual patients demonstrate a range of levels of lethality in two Drosophila melanogaster infection models.

Lutter EI, Faria MM, Rabin HR, Storey DG.

Infect Immun. 2008 May;76(5):1877-88. doi: 10.1128/IAI.01165-07. Epub 2008 Feb 19.

45.

Pulmonary exacerbations in cystic fibrosis.

Rabin HR, Butler SM, Wohl ME, Geller DE, Colin AA, Schidlow DV, Johnson CA, Konstan MW, Regelmann WE; Epidemiologic Study of Cystic Fibrosis.

Pediatr Pulmonol. 2004 May;37(5):400-6.

PMID:
15095322
46.

Pseudomonas aeruginosa quorum-sensing systems may control virulence factor expression in the lungs of patients with cystic fibrosis.

Erickson DL, Endersby R, Kirkham A, Stuber K, Vollman DD, Rabin HR, Mitchell I, Storey DG.

Infect Immun. 2002 Apr;70(4):1783-90.

47.

Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada.

Morgan WJ, Butler SM, Johnson CA, Colin AA, FitzSimmons SC, Geller DE, Konstan MW, Light MJ, Rabin HR, Regelmann WE, Schidlow DV, Stokes DC, Wohl ME, Kaplowitz H, Wyatt MM, Stryker S.

Pediatr Pulmonol. 1999 Oct;28(4):231-41.

PMID:
10497371
48.

Household transmission of Streptococcus pneumoniae, Alberta, Canada.

Kellner JD, Gibb AP, Zhang J, Rabin HR.

Emerg Infect Dis. 1999 Jan-Feb;5(1):154-8. No abstract available.

49.

Impact of microbiology practice on cumulative prevalence of respiratory tract bacteria in patients with cystic fibrosis.

Shreve MR, Butler S, Kaplowitz HJ, Rabin HR, Stokes D, Light M, Regelmann WE.

J Clin Microbiol. 1999 Mar;37(3):753-7.

Supplemental Content

Loading ...
Support Center